{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:52:40Z","timestamp":1790092360001,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40265-023-01929-x","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T09:01:57Z","timestamp":1691744517000},"page":"1323-1329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":179,"title":["Delandistrogene Moxeparvovec: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"issue":"1","key":"1929_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, et al. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"1929_CR2","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1007\/s00415-023-11796-x","volume":"270","author":"M Chang","year":"2023","unstructured":"Chang M, Cai Y, Gao Z, et al. Duchenne muscular dystrophy: pathogenesis and promising therapies. J Neurol. 2023;270(8):3733\u201349.","journal-title":"J Neurol"},{"issue":"4","key":"1929_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S2213-2600(21)00581-6","volume":"10","author":"DJ Birnkrant","year":"2022","unstructured":"Birnkrant DJ, Bello L, Butterfield RJ, et al. Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. Lancet Respir Med. 2022;10(4):403\u201320.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"1929_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/14712598.2020.1725469","volume":"20","author":"DR Asher","year":"2020","unstructured":"Asher DR, Thapa K, Dharia SD, et al. Clinical development on the frontier: gene therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther. 2020;20(3):263\u201374.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"1929_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/14712598.2021.1832462","volume":"21","author":"AE Schneider","year":"2021","unstructured":"Schneider AE, Aartsma-Rus A. Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy. Expert Opin Biol Ther. 2021;21(3):343\u201359.","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"1929_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221097","volume":"14","author":"F Muntoni","year":"2019","unstructured":"Muntoni F, Domingos J, Manzur AY, et al. Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy. PLoS\u00a0One. 2019;14(9): e0221097.","journal-title":"PLoS\u00a0One"},{"issue":"9","key":"1929_CR7","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell JR, Sahenk Z, Lehman K, et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. 2020;77(9):1122\u201331.","journal-title":"JAMA Neurol"},{"key":"1929_CR8","unstructured":"Sarepta Therapeutics Inc. ELEVIDYS (delandistrogene moxeparvovec-rokl) suspension, for intravenous infusion: US prescribing information; 2023. https:\/\/www.fda.gov\/. Accessed 23 Jun 2023."},{"key":"1929_CR9","unstructured":"Sarepta Therapeutics. Sarepta Therapeutics announces FDA approval of ELEVIDYS, the first gene therapy to treat Duchenne muscular dystrophy [media release]; 22 Jun 2023. https:\/\/www.sarepta.com\/."},{"key":"1929_CR10","unstructured":"US Food and Drug Administration. FDA approves first gene therapy for treatment of certain patients with Duchenne muscular dystrophy [media release]; 22 Jun 2023. https:\/\/www.fda.gov\/."},{"key":"1929_CR11","unstructured":"Roche. Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy [media release]; 23 Dec 2019. http:\/\/www.roche.com."},{"key":"1929_CR12","unstructured":"Sarepta Therapeutics. Sarepta Therapeutics and Selecta Biosciences enter into research license and option agreement for Selectas ImmTOR immune tolerance platform in neuromuscular diseases [media release]; 18 Jun 2020. http:\/\/www.sarepta.com."},{"key":"1929_CR13","unstructured":"Chugai Pharmaceutical. Chugai in-licenses gene therapy delandistrogene moxeparvovec (SRP-9001) for Duchenne muscular dystrophy [media release]; 16 Dec 2021. https:\/\/www.chugai-pharm.co.jp\/."},{"key":"1929_CR14","unstructured":"Selecta Biosciences. Selecta Biosciences announces partnership advancements and clinical trial updates [media release]; 13 Jun 2022. http:\/\/www.selectabio.com."},{"key":"1929_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1167762","volume":"11","author":"J Mendell","year":"2023","unstructured":"Mendell J, Shieh P, McDonald C, et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front Cell Dev Biol. 2023;11: 1167762.","journal-title":"Front Cell Dev Biol"},{"key":"1929_CR16","doi-asserted-by":"crossref","unstructured":"Proud C, Zaidman C, McDonald C, et al. One-year data from ENDEAVOR, a phase 1b trial of delandistrogene moxeparvovec in patients with DMD [abstract no. 107 plus oral]. In: Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. 2023.","DOI":"10.1212\/WNL.0000000000203475"},{"issue":"Suppl 1","key":"1929_CR17","first-page":"47","volume":"32","author":"J Malhotra","year":"2022","unstructured":"Malhotra J, Lewis S, Zhang X, et al. Analysis of vector shedding following treatment with delandistrogene moxeparvovec, an investigational rAAVrh74-based gene therapy for DMD [abstract no. LSVP.35 plus poster]. Neuromuscul Disord. 2022;32(Suppl 1):47.","journal-title":"Neuromuscul Disord"},{"key":"1929_CR18","first-page":"1","volume":"11","author":"AC Klimchak","year":"2023","unstructured":"Klimchak AC, Sedita LE, Rodino-Klapac LR, et al. Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States. J Mark Access Health Policy. 2023;11:1\u201314.","journal-title":"J Mark Access Health Policy"},{"key":"1929_CR19","unstructured":"Sarepta Therapeutics. Sarepta Therapeutics reports sustained functional improvement two years after treatment with SRP-9001, its investigational micro-dystrophin gene therapy for Duchenne muscular dystrophy [media release]; 28 Sep 2020. http:\/\/www.sarepta.com."},{"issue":"4 Suppl 1","key":"1929_CR20","first-page":"190","volume":"31","author":"J Mendell","year":"2023","unstructured":"Mendell J, Sahenk Z, Lehman K, et al. Phase 1\/2a trial of delandistrogene moxeparvovec in patients with DMD: 4-year update [abstract no. 354 plus presentation]. Mol Ther. 2023;31(4 Suppl 1):190\u20131.","journal-title":"Mol Ther"},{"key":"1929_CR21","doi-asserted-by":"crossref","unstructured":"Zaidman C, Proud C, McDonald C, et al. One-year data from ENDEAVOR, a phase 1b trial of delandistrogene moxeparvovec in boys with DMD [abstract no. P.129 plus poster]. Neuromuscul Disord. 2022;32(Suppl 1):S101.","DOI":"10.1016\/j.nmd.2022.07.245"},{"key":"1929_CR22","unstructured":"Goedeker NL, Aqul A, Butterfield RJ, et al. Management of patients following investigational delandistrogene moxeparvovec gene therapy for Duchenne muscular dystrophy: Delphi panel consensus considerations based on clinical trial experience [abstract no. 132 plus poster]. Mol Ther. 2023;31(4S1):71."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01929-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01929-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01929-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T09:02:46Z","timestamp":1695200566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01929-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":22,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1929"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01929-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"assertion":[{"value":"11 August 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}